Clinical Features of Psychotic Disorders and Polymorphisms in HT2A, DRD2, DRD4, SLC6A3 (DAT1), and BDNF: A Family Based Association Study

American Journal of Medical Genetics - Neuropsychiatric Genetics

Volumn 125 B, Issue 1, 2004, Pages 69-78

  Fanous, Ayman H ^a,c,g   Neale, M C ^a,c   Straub, R E ^d   Webb, B T ^a,c   O'Neill, A F ^e   Walsh, D ^f   Kendler, K S ^a,b,c  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^e ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^f St Loman's Hospital   (Ireland)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Association study; Genetic; Irish; Schizophrenia; Symptoms

Indexed keywords

BRAIN DERIVED GROWTH FACTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE TRANSPORTER; PROTEIN SLC6A3; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CHROMOSOMAL LOCALIZATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FAMILY STUDY; GENE LOCATION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; NEGATIVE SYNDROME; PEDIGREE ANALYSIS; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOSIS; QUANTITATIVE TRAIT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

EID: 0942268961     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.20103     Document Type: Article

References (103)

1. Abecasis GR, Cardon LR, Cookson WO. 2000. A general test of association for quantitative traits in nuclear families. Am J Hum Genet 66:279-292.
2. Abecasis GR, Cherny SS, Cookson WO, Cardon LR. 2002. Merlin-Rapid analysis of dense genetic maps using sparse gene flow trees. Nat Genet 30:97-101.
3. Addington DD, Azorin JM, Falloon IR, Gerlach J, Hirsch SR, Siris SG. 2002. Clinical issues related to depression in schizophrenia: An international survey of psychiatrists. Acta Psychiatr Scand 105:189-195.
4. Andreasen NC. 1982. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 39:784-788.
5. Andreasen NC, Olsen S. 1982. Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry 39:789-794.
6. Andreasen NC, Ehrhardt JC, Swayze VW, Alliger RJ, Yuh WT, Cohen G, Ziebell S. 1990. Magnetic resonance imaging of the brain in schizophrenia. The pathophysiologic significance of structural abnormalities. Arch Gen Psychiatry 47:35-44.
7. Angrist B, Rotrosen J, Gershon S. 1980. Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology (Berl) 72:17-19.
8. Angrist B, Peselow E, Rubinstein M, Corwin J, Rotrosen J. 1982. Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacology (Berl) 78:128-130.
9. Arango V, Ernsberger P, Marzuk PM, Chen JS, Tierney H, Stanley M, Reis DJ, Mann JJ. 1990. Autoradiographic demonstration of increased serotonin 5-HT2 and beta-adrenergic receptor binding sites in the brain of suicide victims. Arch Gen Psychiatry 47:1038-1047.
10. Arora RC, Meltzer HY. 1989. Serotonergic measures in the brains of suicide victims: 5-HT2 binding sites in the frontal cortex of suicide victims and control subjects. Am J Psychiatry 146:730-736.
11. Bilder RM, Mukherjee S, Rieder RO, Pandurangi AK. 1985. Symptomatic and neuropsychological components of defect states. Schizophr Bull 11: 409-419.
12. Biver F, Wikler D, Lotstra F, Damhaut P, Goldman S, Mendlewicz J. 1997. Serotonin 5-HT2 receptor imaging in major depression: Focal changes in orbito-insular cortex. Br J Psychiatry 171:444-448.
13. Blairy S, Massat I, Staner L, Le Bon O, Van Gestel S, Van Broeckhoven C, Hilger C, Hentges F, Souery D, Mendlewicz J. 2000. 5-HT2a receptor polymorphism gene in bipolar disorder and harm avoidance personality trait. Am J Med Genet 96:360-364.
14. Bleuler E. 1950. Dementia praecox, or the group of schizophrenias. New York: International Universities Press.
15. Brunello N, Masotto C, Steardo L, Markstein R, Racagni G. 1995. New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 13:177-213.
16. Callicott JH, Bertolino A, Egan MF, Mattay VS, Langheim FJ, Weinberger DR. 2000. Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia. Am J Psychiatry 157:1646-1651.
17. Cardno AG, Bowen T, Guy CA, Jones LA, McCarthy G, Williams NM, Murphy KC, Spurlock G, Gray M, Sanders RD, Craddock N, McGuffin P, Owen MJ, O'Donovan MC. 1999. CAG repeat length in the hKCa3 gene and symptom dimensions in schizophrenia. Biol Psychiatry 45:1592-1596.
18. Cardno AG, Sham PC, Murray RM, McGuffin P. 2001. Twin study of symptom dimensions in psychoses. Br J Psychiatry 179:39-45.
19. Cardno AG, Sham PC, Farmer AE, Murray RM, McGuffin P. 2002. Heritability of Schneider's first-rank symptoms. Br J Psychiatry 180: 35-38.
20. Carlsson A, Linquist M. 1963. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20:140-144.
21. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. 2001. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials. Am J Psychiatry 158:518-526.
22. Chee IS, Lee SW, Kim JL, Wang SK, Shin YO, Shin SC, Lee YH, Hwang HM, Lim MR. 2001. 5-HT2A receptor gene promoter polymorphism -1438A/G and bipolar disorder. Psychiatr Genet 11:111-114.
23. Clayton D, Jones H. 1999. Transmission/disequilibrium tests for extended marker haplotypes. Am J Hum Genet 65: 1161-1169.
24. Cook EH Jr, Stein MA, Krasowski MD, Cox NJ, Olkon DM, Kieffer JE, Leventhal BL. 1995. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 56:993-998.
25. Culverhouse R, Suarez BK, Lin J, Reich T. 2002. A perspective on epistasis: Limits of models displaying no main effect. Am J Hum Genet 70:461-471.
26. Curran S, Mill J, Tahir E, Kent L, Richards S, Gould A, Huckett L, Sharp J, Batten C, Fernando S, Ozbay F, Yazgan Y, Simonoff E, Thompson M, Taylor E, Asherson P. 2001. Association study of a dopamine transporter polymorphism and attention deficit hyperactivity disorder in UK and Turkish samples. Mol Psychiatry 6:425-428.
27. D'haenen H, Bossuyt A, Mertens J, Bossuyt-Piron C, Gijsemans M, Kaufman L. 1992. SPECT imaging of serotonin2 receptors in depression. Psychiatry Res 45:227-237.
28. Delgado PL, Price LH, Miller HL, Salomon RM, Aghajanian GK, Heninger GR, Charney DS. 1994. Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry 51:865-874.
29. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR. 2003. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112:257-269.
30. Ellis PM, Salmond C. 1994. Is platelet imipramine binding reduced in depression? A meta-analysis. Biol Psychiatry 36:292-299.
31. Feild HS, Armenakis AA. 1974. On the use of multiple tests of significance in psychological research. Psychol Rep 35:427-431.
32. Ferrer I, Marin C, Rey MJ, Ribalta T, Goutan E, Blanco R, Tolosa E, Marti E. 1999. BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J Neuropathol Exp Neurol 58:729-739.
33. Fulker DW, Cherny SS. 1996. An improved multipoint sib-pair analysis of quantitative traits. Behav Genet 26:527-532.
34. Fulker DW, Cherny SS, Sham PC, Hewitt JK. 1999. Combined linkage and association sib-pair analysis for quantitative traits. Am J Hum Genet 64(1):259-267.
35. Gill M, Daly G, Heron S, Hawi Z, Fitzgerald M. 1997. Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol Psychiatry 2:311-313.
36. Goldman-Rakic PS, Selemon LD. 1997. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull 23:437-458.
37. Gutierrez B, Bertranpetit J, Collier D, Arranz MJ, Valles V, Guillamat R, Van Os J, Fananas L. 1997. Genetic variation of the 5-HT2A receptor gene and bipolar affective disorder. Hum Genet 100:582-584.
38. Hauge XY, Grandy DK, Eubanks JH, Evans GA, Civelli O, Litt M. 1991. Detection and characterization of additional DNA polymorphisms in the dopamine D2 receptor gene. Genomics 10:527-530.
39. Hawi Z, Straub RE, O'Neill A, Kendler KS, Walsh D, Gill M. 1998. No linkage or linkage disequilibrium between brain-derived neurotrophic factor (BDNF) dinucleotide repeat polymorphism and schizophrenia in Irish families. Psychiatry Res 81:111-116.
40. Heiden A, Schussler P, Itzlinger U, Leisch F, Scharfetter J, Gebhardt C, Fuchs K, Willeit M, Nilsson L, Miller-Reiter E, Stompe T, Meszaros K, Sieghart W, Hornik K, Kasper S, Aschauer HN. 2000. Association studies of candidate genes in bipolar disorders. Neuropsychobiology 42(Suppl 1):18-21.
41. Heninger GR, Charney DS, Sternberg DE. 1984. Serotonergic function in depression. Prolactin response to intravenous tryptophan in depressed patients and healthy subjects. Arch Gen Psychiatry 41:398-402.
42. Hoglinger GU, Sautter J, Meyer M, Spenger C, Seiler RW, Oertel WH, Widmer HR. 1998. Rat fetal ventral mesencephalon grown as solid tissue cultures: Influence of culture time and BDNF treatment on dopamine neuron survival and function. Brain Res 813:313-322.
43. Holmes J, Payton A, Barrett JH, Hever T, Fitzpatrick H, Trumper AL, Harrington R, McGuffin P, Owen M, Ollier W, Worthington J, Thapar A. 2000. A family-based and case-control association study of the dopamine D4 receptor gene and dopamine transporter gene in attention deficit hyperactivity disorder. Mol Psychiatry 5:523-530.
44. Kaiser R, Konneker M, Henneken M, Dettling M, Muller-Oerlinghausen B, Roots I, Brockmoller J. 2000. Dopamine D4 receptor 48-bp repeat polymorphism: No association with response to antipsychotic treatment, but association with catatonic schizophrenia. Mol Psychiatry 5:418-424.
45. Kane JM, Freeman HI. 1994. Towards more effective antipsychotic treatment. Br J Psychiatry 165(25):22-31.
46. Kapur S, Seeman P. 2001. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 158:360-369.
47. Kendler KS, Diehl SR. 1993. The genetics of schizophrenia: A current, genetic-epidemiologic perspective. Schizophr Bull 19:261-285.
48. Kendler KS, McGuire M, Gruenberg AM, Walsh D. 1994. Clinical heterogeneity in schizophrenia and the pattern of psychopathology in relatives: results from an epiemiologically base family study. Acta Psychiatr Scand 89:294-300.
49. Kendler KS, O'Neill FA, Burke J, Murphy B, Duke F, Straub RE, Shinkwin R, Ni NM, MacLean CJ, Walsh D. 1996. Irish study on high-density schizophrenia families: Field methods and power to detect linkage. Am J Med Genet 67:179-190.
50. Kendler KS, Myers JM, O'Neill FA, Martin R, Murphy B, MacLean CJ, Walsh D, Straub RE. 2000. Clinical features of schizophrenia and linkage to chromosomes 5q, 6p, 8p, and 10p in the Irish Study of High-Density Schizophrenia Families. Am J Psychiatry 157:402-408.
51. Kraepelin E. 1921. Manic-depressive illiness and paranoia. Edinburgh, Scotland: E & S Livingstone.
52. Krebs MO, Guillin O, Bourdell MC, Schwartz JC, Olie JP, Poirier MF, Sokoloff P. 2000. Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Mol Psychiatry 5:558-562.
53. Labelle C, Leclerc N. 2000. Exogenous BDNF, NT-3, and NT-4 differentially regulate neurite outgrowth in cultured hippocampal neurons. Brain Res Dev Brain Res 123:1-11.
54. Lenzenweger MF, Dworkin RH. 1996. The dimensions of schizophrenia phenomenology. Not one or two, at least three, perhaps four. Br J Psychiatry 168:432-440.
55. Lichter JB, Barr CL, Kennedy JL, Van Tol HH, Kidd KK, Livan JK. 1993. A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Hum Mol Genet 2:767-773.
56. Liddle PF. 1987. The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy. Br J Psychiatry 151:145-151.
57. Lindholm D, Carroll P, Tzimagiogis G, Thoenen H. 1996. Autocrine-paracrine regulation of hippocampal neuron survival by IGF-1 and the neurotrophins BDNF, NT-3, and NT-4. Eur J Neurosci 8:1452-1460.
58. Lowenstein DH, Arsenault L. 1996. The effects of growth factors on the survival and differentiation of cultured dentate gyrus neurons. J Neurosci 16:1759-1769.
59. Mahieu B, Souery D, Lipp O, Mendelbaum K, Verheyen G, De M, Van V, Broeckhoven C, Mendlewicz J. 1997. No association between bipolar affective disorder and a serotonin receptor (5-HT2A) polymorphism. Psychiatry Res 70:65-69.
60. Malhotra AK, Goldman D, Mazzanti C, Clifton A, Breier A, Pickar D. 1998. A functional serotonin transporter (5-HTT) polymorphism is associated with psychosis in neuroleptic-free schizophrenics. Mol Psychiatry 3:328-332.
61. Mann JJ, Stanley M, McBride PA, McEwen BS. 1986. Increased serotonin2 and beta-adrenergic receptor binding in the frontal cortices of suicide victims. Arch Gen Psychiatry 43:954-959.
62. McGlashan TH, Fenton WS. 1991. Classical subtypes for schizophrenia: Literature review for DSM-IV. Schizophr Bull 17:609-632.
63. Muglia P, Vicente AM, Verga M, King N, Macciardi F, Kennedy JL. 2003. Association between the BDNF gene and schizophrenia. Mol Psychiatry 8:146-147.
64. Murer MG, Yan Q, Raisman-Vozari R. 2001. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 63:71-124.
65. Murphy BM, Burke JG, Bray JC, Walsh D, Kendler KS. 1994. An analysis of the clinical features of familial schizophrenia. Acta Psychiatr Scand 89:421-427.
66. Nanko S, Fukuda R, Hattori M, Sasaki T, Dai XY, Kanba S, Kato T, Kazamatsuri H. 1994. Linkage studies between affective disorder and dopamine D2, D3, and D4 receptor gene loci in four Japanese pedigrees. Psychiatry Res 52:149-157.
67. Neves-Pereira M, Mundo E, Muglia P, King N, Macciardi F, Kennedy JL. 2002. The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: Evidence from a family-based association study. Am J Hum Genet 71:651-655.
68. Ozaki N, Rosenthal NE, Pesonen U, Lappalainen J, Feldman-Naim S, Schwartz PJ, Turner EH, Goldman D. 1996. Two naturally occurring amino acid substitutions of the 5-HT2A receptor: similar prevalence in patients with seasonal affective disorder and controls. Biol Psychiatry 40:1267-1272.
69. Proschel M, Saunders A, Roses AD, Muller CR. 1992. Dinucleotide repeat polymorphism at the human gene for the brain-derived neurotrophic factor (BDNF). Hum Mol Genet 1:353.
70. Rice DP. 1999. The economic impact of schizophrenia. J Clin Psychiatry 60(Suppl 1):4-6.
71. Riley BP, McGuffin P. 2000. Linkage and associated studies of schizophrenia. Am J Med Genet 97:23-44.
72. Risch N. 1990. Linkage strategies for genetically complex traits. I. Multilocus models. Am J Hum Genet 46:222-228.
73. Sanfilipo M, Lafargue T, Rusinek H, Arena L, Loneragan C, Lautin A, Feiner D, Rotrosen J, Wolkin A. 2000. Volumetric measure of the frontal and temporal lobe regions in schizophrenia: Relationship to negative symptoms. Arch Gen Psychiatry 57:471-480.
74. Sasaki T, Dai XY, Kuwata S, Fukuda R, Kunugi H, Hattori M, Nanko S. 1997. Brain-derived neurotrophic factor gene and schizophrenia in Japanese subjects. Am J Med Genet 74:443-444.
75. Seeman P, Madras BK. 1998. Anti-hyperactivity medication: Methylphenidate and amphetamine. Mol Psychiatry 3:386-396.
76. Serretti A, Lattuada E, Lorenzi C, Lilli R, Smeraldi E. 2000. Dopamine receptor D2 Ser/Cys 311 variant is associated with delusion and disorganization symptomatology in major psychoses. Mol Psychiatry 5:270-274.
77. Serretti A, Lilli R, Lorenzi C, Lattuada E, Smeraldi E. 2001. DRD4 exon 3 variants associated with delusional symptomatology in major psychoses: A study on 2,011 affected subjects. Am J Med Genet 105:283-290.
78. Siever LJ, Murphy DL, Slater S, de l V, Lipper S. 1984. Plasma prolactin changes following fenfluramine in depressed patients compared to controls: An evaluation of central serotonergic responsivity in depression. Life Sci 34:1029-1039.
79. Soontornniyomkij V, Wang G, Pittman CA, Hamilton RL, Wiley CA, Achim CL. 1999. Absence of brain-derived neurotrophic factor and trkB receptor immunoreactivity in glia of Alzheimer's disease. Acta Neuropathol (Berl) 98:345-348.
80. Spielman RS, McGinnis RE, Ewens WJ. 1993. Transmission test for linkage disequilibrium: The insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet 52:506-516.
81. Spitzer RL, Williams JB, Gibbon J. 1979. Structured Clinical Interview for DSM-III-R Patient Version.
82. Straub RE, Speer MC, Luo Y, Rojas K, Overhauser J, Ott J, Gilliam TC. 1993. A microsatellite genetic linkage map of human chromosome 18. Genomics 15:48-56.
83. Straub RE, Sullivan PF, Ma Y, Myakishev MV, Harris-Kerr C, Wormley B, Kadambi B, Sadek H, Silverman MA, Webb BT, Neale MC, Bulik CM, Joyce PR, Kendler KS. 1999. Susceptibility genes for nicotine dependence: A genome scan and followup in an independent sample suggest that regions on chromosomes 2, 4, 10, 16, 17, and 18 merit further study. Mol Psychiatry 4:129-144.
84. Straub RE, MacLean CJ, Ma Y, Webb BT, Myakishev MV, Harris-Kerr C, Wormley B, Sadek H, Kadambi B, O'Neill FA, Walsh D, Kendler KS. 2002. Genome-wide scans of three independent sets of 90 Irish multiplex schizophrenia families and follow-up of selected regions in all families provides evidence for multiple susceptibility genes. Mol Psychiatry 7:542-559.
85. Sullivan PF, Eaves LJ, Kendler KS, Neale MC. 2001. Genetic case-control association studies in neuropsychiatry. Arch Gen Psychiatry 58:1015-1024.
86. Turetsky B, Cowell PE, Gur RC, Grossman RI, Shtasel DL, Gur RE. 1995. Frontal and temporal lobe brain volumes in schizophrenia. Relationship to symptoms and clinical subtype. Arch Gen Psychiatry 52:1061-1070.
87. Tut TG, Wang JL, Lim CC. 2000. Negative association between T102C polymorphism at the 5-HT2A receptor gene and bipolar affective disorders in Singaporean Chinese. J Affect Disord 58:211-214.
88. Vandenbergh DJ, Persico AM, Uhl GR. 1992. A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dirnorphic TaqI RFLPs. Brain Res Mol Brain Res 15:161-166.
89. van Kammen DP, Boronow JJ. 1988. Dextro-amphetamine diminishes negative symptoms in schizophrenia. Int Clin Psychopharmacol 3:111-121.
90. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O. 1991. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610-614.
91. Virgos C, Martorell L, Valero J, Figuera L, Civeira F, Joven J, Labad A, Vilella E. 2001. Association study of schizophrenia with polymorphisms at six candidate genes. Schizophr Res 49:65-71.
92. Warren JT Jr, Peacock ML, Rodreigues LC, Fink JK. 1993. An MspI polymorphism in the human serotonin receptor gene (HTR2): detection by DGGE and RFLP analysis. Hum Mol Genet 2:338.
93. Wassink TH, Nelson JJ, Crowe RR, Andreasen NC. 1999. Heritability of BDNF alleles and their effect on brain morphology in schizophrenia. Am J Med Genet 88:724-728.
94. Weinberger DR. 1987. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44:660-669.
95. Wible CG, Anderson J, Shenton ME, Kricun A, Hirayasu Y, Tanaka S, Levitt JJ, O'Donnell BF, Kikinis R, Jolesz FA, McCarley RW. 2001. Prefrontal cortex, negative symptoms, and schizophrenia: An MRI study. Psychiatry Res 108:65-78.
96. Woods BT. 1998. Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism. Am J Psychiatry 155:1661-1670.
97. Xu J, Turner A, Little J, Bleecker ER, Meyers DA. 2002. Positive results in association studies are associated with departure from Hardy-Weinberg equilibrium: Hint for genotyping error? Hum Genet 111:573-574.
98. Yatham LN, Liddle PF, Shiah IS, Scarrow G, Lam RW, Adam MJ, Zis AP, Ruth TJ. 2000. Brain serotonin2 receptors in major depression: A positron emission tomography study. Arch Gen Psychiatry 57:850-858.
99. Ying SW, Futter M, Rosenblum K, Webber MJ, Hunt SP, Bliss TV, Bramham CR. 2002. Brain-derived neurotrophic factor induces long-term potentiation in intact adult hippocampus: Requirement for ERK activation coupled to CREB and upregulation of Arc synthesis. J Neurosci 22:1532-1540.
100. Youngren KD, Inglis FM, Pivirotto PJ, Jedema HP, Bradberry CW, Goldman-Rakic PS, Roth RH, Moghaddam B. 1999. Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with the caudate nucleus. Neuropsychopharmacology 20:403-412.
101. Zhang HY, Ishigaki T, Tani K, Chen K, Shih JC, Miyasato K, Ohara K, Ohara K. 1997. Serotonin2A receptor gene polymorphism in mood disorders. Biol Psychiatry 41:768-773.
102. Zhang XY, Zhou DF, Zhang PY, Wei J. 2000. The CCK-A receptor gene possibly associated with positive symptoms of schizophrenia. Mol Psychiatry 5:239-240.
103. Zhou J, Bradford HF, Stern GM. 1994. The response of human and rat fetal ventral mesencephalon in culture to the brain-derived neurotrophic factor treatment. Brain Res 656:147-156.